ATE432702T1 - Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen - Google Patents

Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen

Info

Publication number
ATE432702T1
ATE432702T1 AT04789487T AT04789487T ATE432702T1 AT E432702 T1 ATE432702 T1 AT E432702T1 AT 04789487 T AT04789487 T AT 04789487T AT 04789487 T AT04789487 T AT 04789487T AT E432702 T1 ATE432702 T1 AT E432702T1
Authority
AT
Austria
Prior art keywords
obesity
aminobenzimidazoles
treatment
concentrating hormone
receptor antagonists
Prior art date
Application number
AT04789487T
Other languages
English (en)
Inventor
Thavalakulamgara Sasikumar
Duane Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE432702T1 publication Critical patent/ATE432702T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT04789487T 2003-10-02 2004-09-30 Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen ATE432702T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50802703P 2003-10-02 2003-10-02
PCT/US2004/032494 WO2005034947A1 (en) 2003-10-02 2004-09-30 Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

Publications (1)

Publication Number Publication Date
ATE432702T1 true ATE432702T1 (de) 2009-06-15

Family

ID=34434893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04789487T ATE432702T1 (de) 2003-10-02 2004-09-30 Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen

Country Status (10)

Country Link
US (1) US7030113B2 (de)
EP (1) EP1667679B1 (de)
JP (1) JP2007507533A (de)
CN (1) CN1859907A (de)
AT (1) ATE432702T1 (de)
CA (1) CA2540845C (de)
DE (1) DE602004021399D1 (de)
ES (1) ES2326980T3 (de)
MX (1) MXPA06003738A (de)
WO (1) WO2005034947A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
EP1773822B1 (de) * 2004-07-16 2009-06-17 Shering Corporation Heterocyclylverbindungen als selektive antagonisten am rezeptor für das melaninkonzentrierende hormon zur behandlung von obesitas und verwandten erkrankungen
WO2007039462A2 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as mch receptor antagonists
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
EP2538784B1 (de) * 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazolderivate als antidiabetika
EP2677869B1 (de) * 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Neue cyclische azabenzimidazolderivate als antidiabetika

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
HUP0500034A2 (hu) * 2001-12-04 2005-04-28 Schering Corporation N-Aril-N'-(aril-cikloalkil)-karbamid-származékok mint MCH antagonisták és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
CA2472470A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
AU2003266668A1 (en) * 2002-09-30 2004-04-23 Banyu Pharmaceutical Co., Ltd. 2-aminobenzimidazole derivative
WO2004100875A2 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
US20050085488A1 (en) 2005-04-21
ES2326980T3 (es) 2009-10-22
JP2007507533A (ja) 2007-03-29
CN1859907A (zh) 2006-11-08
MXPA06003738A (es) 2006-06-14
US7030113B2 (en) 2006-04-18
DE602004021399D1 (de) 2009-07-16
WO2005034947A1 (en) 2005-04-21
CA2540845C (en) 2010-11-09
EP1667679B1 (de) 2009-06-03
EP1667679A1 (de) 2006-06-14
CA2540845A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
WO2003045918A8 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
NO20050745L (no) Nye amidforbindelser med MCH-antagonistisk effekt, og medikamenter inneholdende slike forbindelser
MX2007004306A (es) Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados.
NO20050749L (no) Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
EA200101019A1 (ru) Модуляторы рецепторов глюкокортикоидов
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
EA200601239A1 (ru) Замещённые хинолиновые соединения
TW200609231A (en) Mglur1 antagonists as therapeutic agents
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
MX2008002366A (es) Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos.
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
TW200740826A (en) Fused tricyclic mGluR1 antagonists as therapeutic agents
MXPA05009193A (es) Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.
ATE432702T1 (de) Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen
EA200501594A1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
MXPA05013596A (es) Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties